Skip to main content
Log in

p-Glycoprotein expression in malignant melanoma

  • Original Papers
  • Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Summary

In some human malignancies resistance to chemotherapy is caused by an energy-dependent efflux system, responsible for the removal of chemotherapeutics out of the resistant tumor cells. A major component of this efflux system is the permeability glycoprotein (p-glycoprotein), which depends on the multidrug-resistance geneMDR1.

We have tested p-glycoprotein in primary and metastatic human melanoma by use of the monoclonal antibody C219; a substantial expression was only observed in 1/37 primary melanomas and in 1/27 melanoma metastases. None of the patients with negative metastases responded to chemotherapy. Moreover a complete remission of metastasic growth was observed in the patient with the metastasis significantly expressing the p-glycoprotein. Sequential studies revealed no significant increase of p-glycoprotein-positive cells during and after chemotherapy. We conclude that drug resistance in human melanoma does not usually depend on the p-glycoprotein-related efflux system. Other mechanisms are obviously responsible for drug resistance in this human malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • De Vita VT, Hellmann S, Rosenberg SA (1985) Cancer: principles and practices of oncology, 2nd ed. Lippincott, Philadelphia

    Google Scholar 

  • Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S-L, Gazdar A, Pirker R, Green A, Christ W, Brodeur GM, Lieber M, Cossmann J, Gottesmann MM, Pastan I (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116–124

    Google Scholar 

  • Kartner N, Evernden-Porelle D, Bradley G, Ling V (1985) Detection of p-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316:820–823

    Google Scholar 

  • Lemontt JF, Azzaria M, Gros P (1988) Increasedmdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells. Cancer Res 48:6348–6353

    Google Scholar 

  • Mattern J, Volm M (1989) P-Glycoprotein als Resistenz-Marker in Tumoren. Dtsch Med Wochenschr 114:1979–1981

    Google Scholar 

  • Ostmeier H, Suter L (1989) The Ki-67 antigen in primary human melanomas — its relationship to mitotic rate and tumor thickness and its stability. Arch Dermatol Res 281:173–177

    Google Scholar 

  • Roninson JB (1987) Molecular mechanism of multidrug resistance in tumor cells. Clin Physiol Biochem 5:140–151

    Google Scholar 

  • Stacher A, Moser K (1986) Chemotherapie maligner Erkrankungen 3. Aufl Deutscher Ärzteverlag, Köln

    Google Scholar 

  • Suter L, Bröcker E-B, Ostmeier H, Schumann J, Sorg C (1989) Metastatic human melanoma. Phenotypic heterogenity and antigen expression in relation to the clinical status. J Cancer Res Clin Oncol 115:459–464

    Google Scholar 

  • Thiebaut F, Tsuruo T, Hamada H, Gottesmann MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product p-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735–7738

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

This work was supported by the Deutsche Krebshilfe (grant M 55/85/Su1)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fuchs, B., Ostmeier, H. & Suter, L. p-Glycoprotein expression in malignant melanoma. J Cancer Res Clin Oncol 117, 168–171 (1991). https://doi.org/10.1007/BF01613142

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01613142

Key words

Navigation